The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but there are several areas in which the rule could be amended, AHA said today. Specifically, the AHA urged HRSA to develop a “fast-track process” to provide 340B hospitals and other covered entities access to 340B drug ceiling prices, which “would help ensure a level-playing field in the dispute resolution process,” AHA Executive Vice President Tom Nickels said in a comment letter on the proposed rule. Among other proposals, AHA also commented on the ADR panel composition and decisions; information requests; and claims initiation and consolidation.

Related News Articles

Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…